Duchenne Muscular Dystrophy Drugs Market by Product Type (Corticosteroids, Pain Management Drugs), Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy), End User (Hospitals, Clinics, Home Care Settings), and Region 2024-2032
The global Duchenne muscular dystrophy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 9.96% during 2024-2032. The rising prevalence of Duchenne muscular dystrophy among the masses, the increasing number of new product approvals and launches, and favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, represent some of the key factors driving the market.
Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles. The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based. Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.
Duchenne Muscular Dystrophy Drugs Market Trends:
The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market. Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for underserved categories, such as infants, females, and nonambulant patients, are propelling the market. However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market. On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global Duchenne muscular dystrophy drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product type, therapeutic approach, and end user.
Product Type Insights:
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Pain Management Drugs
The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the product type. This includes corticosteroids (prednisolone, prednisone, and deflazacort) and pain management drugs. According to the report, corticosteroids represented the largest segment.
Therapeutic Approach Insights:
Mutation Suppression
Exon Skipping
Steroid Therapy
The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the therapeutic approach. This includes mutation suppression, exon skipping, and steroid therapy. According to the report, exon skipping represented the largest segment.
End User Insights:
Hospitals
Clinics
Home Care Settings
A detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and home care settings. According to the report, hospitals accounted for the largest market share.
Regional Insights:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for Duchenne muscular dystrophy drugs. Some of the factors driving the North America Duchenne muscular dystrophy drugs market include the rising number of new product approvals and launches, continual improvements in medical infrastructure, and the presence of several key players in the country.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global Duchenne muscular dystrophy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include FibroGen Inc., Italfarmaco S.p.A., NS Pharma Inc. (Nippon Shinyaku Co. Ltd.), PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report
1. How big is the global Duchenne muscular dystrophy drugs market?
2. What is the expected growth rate of the global Duchenne muscular dystrophy drugs market during 2024-2032?
3. What are the key factors driving the global Duchenne muscular dystrophy drugs market?
4. What has been the impact of COVID-19 on the global Duchenne muscular dystrophy drugs market?
5. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the product type?
6. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the therapeutic approach?
7. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the end user?
8. What are the key regions in the global Duchenne muscular dystrophy drugs market?
9. Who are the key players/companies in the global Duchenne muscular dystrophy drugs market?
Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles. The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based. Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.
Duchenne Muscular Dystrophy Drugs Market Trends:
The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market. Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for underserved categories, such as infants, females, and nonambulant patients, are propelling the market. However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market. On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global Duchenne muscular dystrophy drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product type, therapeutic approach, and end user.
Product Type Insights:
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Pain Management Drugs
The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the product type. This includes corticosteroids (prednisolone, prednisone, and deflazacort) and pain management drugs. According to the report, corticosteroids represented the largest segment.
Therapeutic Approach Insights:
Mutation Suppression
Exon Skipping
Steroid Therapy
The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the therapeutic approach. This includes mutation suppression, exon skipping, and steroid therapy. According to the report, exon skipping represented the largest segment.
End User Insights:
Hospitals
Clinics
Home Care Settings
A detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and home care settings. According to the report, hospitals accounted for the largest market share.
Regional Insights:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for Duchenne muscular dystrophy drugs. Some of the factors driving the North America Duchenne muscular dystrophy drugs market include the rising number of new product approvals and launches, continual improvements in medical infrastructure, and the presence of several key players in the country.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global Duchenne muscular dystrophy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include FibroGen Inc., Italfarmaco S.p.A., NS Pharma Inc. (Nippon Shinyaku Co. Ltd.), PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report
1. How big is the global Duchenne muscular dystrophy drugs market?
2. What is the expected growth rate of the global Duchenne muscular dystrophy drugs market during 2024-2032?
3. What are the key factors driving the global Duchenne muscular dystrophy drugs market?
4. What has been the impact of COVID-19 on the global Duchenne muscular dystrophy drugs market?
5. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the product type?
6. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the therapeutic approach?
7. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the end user?
8. What are the key regions in the global Duchenne muscular dystrophy drugs market?
9. Who are the key players/companies in the global Duchenne muscular dystrophy drugs market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT TYPE
6.1 Corticosteroids
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Prednisolone
6.1.2.2 Prednisone
6.1.2.3 Deflazacort
6.1.3 Market Forecast
6.2 Pain Management Drugs
6.2.1 Market Trends
6.2.2 Market Forecast
7 MARKET BREAKUP BY THERAPEUTIC APPROACH
7.1 Mutation Suppression
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Exon Skipping
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Steroid Therapy
7.3.1 Market Trends
7.3.2 Market Forecast
8 MARKET BREAKUP BY END USER
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Home Care Settings
8.3.1 Market Trends
8.3.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 DRIVERS, RESTRAINTS, AND OPPORTUNITIES
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 FibroGen Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Italfarmaco S.p.A.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 PTC Therapeutics Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Santhera Pharmaceuticals
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Sarepta Therapeutics Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY PRODUCT TYPE
6.1 Corticosteroids
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Prednisolone
6.1.2.2 Prednisone
6.1.2.3 Deflazacort
6.1.3 Market Forecast
6.2 Pain Management Drugs
6.2.1 Market Trends
6.2.2 Market Forecast
7 MARKET BREAKUP BY THERAPEUTIC APPROACH
7.1 Mutation Suppression
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Exon Skipping
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Steroid Therapy
7.3.1 Market Trends
7.3.2 Market Forecast
8 MARKET BREAKUP BY END USER
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Home Care Settings
8.3.1 Market Trends
8.3.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 DRIVERS, RESTRAINTS, AND OPPORTUNITIES
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 FibroGen Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Italfarmaco S.p.A.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 PTC Therapeutics Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Santhera Pharmaceuticals
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Sarepta Therapeutics Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
LIST OF TABLES
Table 1: Global: Duchenne Muscular Dystrophy Drugs Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
Table 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Therapeutic Approach (in Million US$), 2024-2032
Table 4: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 5: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Duchenne Muscular Dystrophy Drugs Market: Competitive Structure
Table 7: Global: Duchenne Muscular Dystrophy Drugs Market: Key Players
Table 1: Global: Duchenne Muscular Dystrophy Drugs Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
Table 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Therapeutic Approach (in Million US$), 2024-2032
Table 4: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 5: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Duchenne Muscular Dystrophy Drugs Market: Competitive Structure
Table 7: Global: Duchenne Muscular Dystrophy Drugs Market: Key Players
LIST OF FIGURES
Figure 1: Global: Duchenne Muscular Dystrophy Drugs Market: Major Drivers and Challenges
Figure 2: Global: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Product Type (in %), 2023
Figure 5: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Therapeutic Approach (in %), 2023
Figure 6: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by End User (in %), 2023
Figure 7: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Region (in %), 2023
Figure 8: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: North America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: North America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: United States: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: United States: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Canada: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Canada: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: China: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: China: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Japan: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Japan: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: India: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: India: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: South Korea: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: South Korea: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Australia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Australia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Indonesia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Indonesia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Europe: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Europe: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Germany: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Germany: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: France: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: France: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: United Kingdom: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: United Kingdom: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Italy: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Italy: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Spain: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Spain: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Russia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Russia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Latin America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Latin America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Brazil: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Brazil: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Mexico: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Mexico: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Breakup by Country (in %), 2023
Figure 72: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Global: Duchenne Muscular Dystrophy Drugs Industry: Drivers, Restraints, and Opportunities
Figure 74: Global: Duchenne Muscular Dystrophy Drugs Industry: Value Chain Analysis
Figure 75: Global: Duchenne Muscular Dystrophy Drugs Industry: Porter's Five Forces Analysis
Figure 1: Global: Duchenne Muscular Dystrophy Drugs Market: Major Drivers and Challenges
Figure 2: Global: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Product Type (in %), 2023
Figure 5: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Therapeutic Approach (in %), 2023
Figure 6: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by End User (in %), 2023
Figure 7: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Region (in %), 2023
Figure 8: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: North America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: North America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: United States: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: United States: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Canada: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Canada: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: China: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: China: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Japan: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Japan: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: India: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: India: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: South Korea: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: South Korea: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Australia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Australia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Indonesia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Indonesia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Europe: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Europe: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Germany: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Germany: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: France: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: France: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: United Kingdom: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: United Kingdom: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Italy: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Italy: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Spain: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Spain: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Russia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Russia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Latin America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Latin America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Brazil: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Brazil: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Mexico: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Mexico: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Breakup by Country (in %), 2023
Figure 72: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Global: Duchenne Muscular Dystrophy Drugs Industry: Drivers, Restraints, and Opportunities
Figure 74: Global: Duchenne Muscular Dystrophy Drugs Industry: Value Chain Analysis
Figure 75: Global: Duchenne Muscular Dystrophy Drugs Industry: Porter's Five Forces Analysis
